May 15 (Reuters) - Aerie Pharmaceuticals Inc:
* AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%
* AERIE PHARMACEUTICALS - EXPECTED FDA REVIEW PERIOD FOR ROCLATAN NDA IS TEN MONTHS
* AERIE PHARMACEUTICALS INC - NDA SUBMITTED AS A 505(B)(2) WITH AN EXPECTED TEN-MONTH FDA REVIEW Source text for Eikon: Further company coverage: